Literature DB >> 23985417

Does study partner type impact the rate of Alzheimer's disease progression?

Joshua D Grill1, Yan Zhou, Jason Karlawish, David Elashoff.   

Abstract

Most patients with Alzheimer's disease (AD) do not have a spouse. Despite this, the majority of AD research participants enroll with a spouse study partner. It remains unclear if differences between AD patients who do and do not have a spouse may bias study results. In this study, we examined whether AD patients with different study partner types (spouse versus adult child) demonstrate different rates of disease progression over two years on three outcome measures commonly used in AD research, including clinical trials. We used data from the National Alzheimer's Coordinating Center Uniform Data Set to examine disease progression in participants age 55-90 with probable AD dementia. We examined disease progression as measured by the Clinical Dementia Rating Scale-Sum of the Boxes score, the Mini Mental Status Examination, and the Functional Assessment Questionnaire. Analyses were performed on data for all available eligible participants from the NACC UDS and after performing a propensity-matching model to better account for inherent differences between the populations of interest. Propensity matching was successful only when models did not include age and gender. For both propensity-matched analyses and those of all available data, we did not observe any differences between the study partner populations for any outcome measure. These results suggest that if investigators can improve in recruiting AD patients with adult child caregivers to research, the implications to study results may be minimal.

Entities:  

Keywords:  Adult children; Alzheimer's disease; caregivers; clinical trial; disease progression; spouses

Mesh:

Year:  2014        PMID: 23985417      PMCID: PMC3842422          DOI: 10.3233/JAD-131052

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  26 in total

1.  Organized outpatient care: stroke prevention clinic referrals are associated with reduced mortality after transient ischemic attack and ischemic stroke.

Authors:  Fiona Webster; Gustavo Saposnik; Moira K Kapral; Jiming Fang; Chris O'Callaghan; Vladimir Hachinski
Journal:  Stroke       Date:  2011-09-15       Impact factor: 7.914

2.  The Clinical Dementia Rating (CDR): current version and scoring rules.

Authors:  J C Morris
Journal:  Neurology       Date:  1993-11       Impact factor: 9.910

3.  Measurement of functional activities in older adults in the community.

Authors:  R I Pfeffer; T T Kurosaki; C H Harrah; J M Chance; S Filos
Journal:  J Gerontol       Date:  1982-05

4.  Referral to an extracorporeal membrane oxygenation center and mortality among patients with severe 2009 influenza A(H1N1).

Authors:  Moronke A Noah; Giles J Peek; Simon J Finney; Mark J Griffiths; David A Harrison; Richard Grieve; M Zia Sadique; Jasjeet S Sekhon; Daniel F McAuley; Richard K Firmin; Christopher Harvey; Jeremy J Cordingley; Susanna Price; Alain Vuylsteke; David P Jenkins; David W Noble; Roxanna Bloomfield; Timothy S Walsh; Gavin D Perkins; David Menon; Bruce L Taylor; Kathryn M Rowan
Journal:  JAMA       Date:  2011-10-05       Impact factor: 56.272

5.  Quality of life of patients with Alzheimer's disease: differential perceptions between spouse and adult child caregivers.

Authors:  J L Conde-Sala; J Garre-Olmo; O Turró-Garriga; J Vilalta-Franch; S López-Pousa
Journal:  Dement Geriatr Cogn Disord       Date:  2010-02-11       Impact factor: 2.959

6.  Improving caregiver well-being delays nursing home placement of patients with Alzheimer disease.

Authors:  Mary S Mittelman; William E Haley; Olivio J Clay; David L Roth
Journal:  Neurology       Date:  2006-11-14       Impact factor: 9.910

7.  A matched case control study with propensity score balancing examining the protective effect of paracetamol against parentally reported apnoea in infants.

Authors:  Paul Walsh; Lucas Shanholtzer; Mark Loewen; Kim Trinh; Ben McEnulty; Stephen J Rothenberg
Journal:  Resuscitation       Date:  2011-12-14       Impact factor: 5.262

8.  Effect of study partner on the conduct of Alzheimer disease clinical trials.

Authors:  Joshua D Grill; Rema Raman; Karin Ernstrom; Paul Aisen; Jason Karlawish
Journal:  Neurology       Date:  2012-12-19       Impact factor: 9.910

Review 9.  Potential ethnic modifiers in the assessment and treatment of Alzheimer's disease: challenges for the future.

Authors:  Warachal E Faison; Susan K Schultz; Jeroen Aerssens; Jennifer Alvidrez; Ravi Anand; Lindsay A Farrer; Lissy Jarvik; Jennifer Manly; Thomas McRae; Greer M Murphy; Jason T Olin; Darrel Regier; Mary Sano; Jacobo E Mintzer
Journal:  Int Psychogeriatr       Date:  2007-04-23       Impact factor: 3.878

10.  Factors related to perceived quality of life in patients with Alzheimer's disease: the patient's perception compared with that of caregivers.

Authors:  Josep Lluís Conde-Sala; Josep Garre-Olmo; Oriol Turró-Garriga; Secundino López-Pousa; Joan Vilalta-Franch
Journal:  Int J Geriatr Psychiatry       Date:  2009-06       Impact factor: 3.485

View more
  4 in total

1.  Participant-Informant Relationships Affect Quality of Life Ratings in Incipient and Clinical Alzheimer Disease.

Authors:  Amy Lin; Jenny Brook; Joshua D Grill; Edmond Teng
Journal:  Am J Geriatr Psychiatry       Date:  2016-10-13       Impact factor: 4.105

2.  Study partners perform essential tasks in dementia research and can experience burdens and benefits in this role.

Authors:  Betty S Black; Holly A Taylor; Peter V Rabins; Jason Karlawish
Journal:  Dementia (London)       Date:  2016-05-13

3.  Frequency and impact of informant replacement in Alzheimer disease research.

Authors:  Joshua D Grill; Yan Zhou; Jason Karlawish; David Elashoff
Journal:  Alzheimer Dis Assoc Disord       Date:  2015 Jul-Sep       Impact factor: 2.703

4.  Researchers' perspectives on the role of study partners in dementia research.

Authors:  Betty S Black; Holly Taylor; Peter V Rabins; Jason Karlawish
Journal:  Int Psychogeriatr       Date:  2014-07-03       Impact factor: 3.878

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.